Source-grounded facts extracted from ZEVRA THERAPEUTICS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ZEVRA THERAPEUTICS, INC. shareholders rejected Approve an amendment to the Restated Certificate of Incorporation to phase out the classified Board structure and provide that all directors elected at or after the 2027 annual meeting be elected on an annual basis at the 2026-06-04 meeting.
“Proposal 3 — Vote to Approve an Amendment to the Charter to Declassify the Board: For Against Abstain Broker Non-Votes 32,557,653 1,145,079 16,950 12,606,934”
ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of Ernst & Young LLP as the Company's Independent Registered Public Accounting Firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal 2 — Ratification of Ernst & Young LLP as the Company’s Independent Registered Public Accounting Firm: For Against Abstain Broker Non-Votes 45,947,281 234,753 144,582 —”
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Class II Directors at the 2026-06-04 meeting.
“At the 2026 Annual Meeting of Stockholders of Zevra Therapeutics, Inc. (the “Company”) held on June 4, 2026 (the “Annual Meeting”), the stockholders of the Company voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 20, 2026 (File No. 001-36913) (the “Proxy Statement”): (1) to elect Douglas W. Calder and Corey Watton to the Company’s Board as Class II directors to hold office until the 2029 annual meeting of stockholders, and until their respective successors shall have been duly elected and qualified (“Proposal 1”)”
ZEVRA THERAPEUTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $36.2 million, net income $37.9 million, EPS $0.62 per basic and $0.60 diluted share.
“set forth by specific reference in any such filing. --- EX-99.1 (EX-99.1) --- Zevra Reports First Quarter 2026 Financial Results and Corporate Update Q1 2026 net revenue of $36.2 million, a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to”
ZEVRA THERAPEUTICS, INC. terminated Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., Perceptive Credit Holdings IV, LP, and Alter Domus (US) LLC valued at $63.0 million (effective 2026-03-12).
“On March 12, 2026, the Company repaid in full all outstanding obligations under that certain Credit Agreement, dated as of April 5, 2024, by and among the Company, HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP (collectively, the “Lenders”), and Alter Domus (US) LLC, as administrative agent (the “Credit Agreement”).”
ZEVRA THERAPEUTICS, INC. entered into Asset Purchase and Settlement Agreement with Commave Therapeutics SA valued at $50.0 million (effective 2026-03-13).
“On March 13, 2026, Zevra Therapeutics, Inc.(the “Company”) entered into an Asset Purchase and Settlement Agreement (the “Agreement”) with Commave Therapeutics SA (“Commave”) to sell certain assets of the Company to Commave and to resolve litigation pending in the Court of Chancery of the State of Delaware captioned Commave Therapeutics SA v. Zevra Therapeutics, Inc., C.A. No. 2024-0920-LWW (the “Litigation”) related to claims arising under the Collaboration and License Agreement between the parties dated September 3, 2019, as amended (the “AZSTARYS License Agreement”).”
ZEVRA THERAPEUTICS, INC. reported the full year ended December 31, 2025 results: revenue $106.5 million, net income Net income of $83.2 million, EPS $1.40 per basic and $1.35 per diluted share.
“--- Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Q4 net revenue of $34.1 million, representing 31% growth quarter-over-quarter FY 2025 net revenue of $106.5 million , driven by growth in MIPLYFFA ® net revenue to $87.4 million 2025 EPS of $1.40 basic and $1.35 diluted Company to host conference call and webcast TODAY, March 9, 2026, at 4:30”
ZEVRA THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2025 results: revenue $34.1 million.
“Zevra Reports Fourth Quarter and Full Year 2025 Financial Results Q4 net revenue of $34.1 million”
ZEVRA THERAPEUTICS, INC. completed a disposition for $150.0 million (closed 2025-04-01).
“the terms of an asset purchase agreement, dated February 26, 2025 (the “PRV Transfer Agreement”). Pursuant to the PRV Transfer Agreement, the Company received gross proceeds of $150.0 million from the buyer upon the closing of the Asset Sale. The foregoing description of the PRV Transfer Agreement does not purport to be complete and is qualified in its entirety by the”
ZEVRA THERAPEUTICS, INC. shareholders rejected Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan at the 2024-05-13 meeting.
“4. Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan 4,143,728 16,964,060 221,241 9,865,186”
ZEVRA THERAPEUTICS, INC. shareholders approved Advisory approval of compensation of named executive officers at the 2024-05-13 meeting.
“3. Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,215 9,888,153 273,661 9,865,186”
ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-13 meeting.
“2. Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company ’ s fiscal year ending December 31, 2024. 22,543,306 7,352,086 1,298,823 —”
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Alvin Shih, M.D. as a Class III director at the 2024-05-13 meeting.
“Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.”
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Neil F. McFarlane as a Class III director at the 2024-05-13 meeting.
“Anderson 15,266,761 6,062,268 9,865,186 Neil F. McFarlane 12,413,828 8,915,201 9,865,186 Alvin Shih, M.D. 16,592,152 4,736,877 9,865,186 For Against Abstentions Broker Non-Votes 2.”
ZEVRA THERAPEUTICS, INC. shareholders approved Election of Thomas D. Anderson as a Class III director at the 2024-05-13 meeting.
“1. Election of Directors For Withheld Broker Non-Votes Thomas D. Anderson 15,266,761 6,062,268 9,865,186”
ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2024 results: revenue $3.4 million, net income ($16.6) million, EPS ($0.40) per basic and diluted share.
“patients currently enrolled and to preserve the value of the program while conducting our portfolio review. Overview of Q1 2024 Financial Results: Net revenue for Q1 2024 was $3.4 million, compared to net revenue of $3.2 million in Q1 2023. The components of revenue during the first quarter included $2.2 million in net reimbursements from the French EAP for”
ZEVRA THERAPEUTICS, INC. incurred credit facility of $100.0 million with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP at 3-Month Term SOFR plus 7.00% per annum maturing fifth anniversary of the Closing Date.
“the Lenders provided a senior secured loan facility to the Company in the aggregate principal amount of $100.0 million (the “Debt Financing”).”
ZEVRA THERAPEUTICS, INC. terminated Note Purchase Agreement with Nantahala Capital Management, LLC (effective 2024-04-04).
“On April 4, 2024, in connection with the Debt Financing, the Company delivered to Nantahala Capital Management, LLC ("NCM"), certain of its affiliates and certain other parties (collectively with NCM, "Nantahala") a payoff letter in connection with its repayment of amounts outstanding under the Note Purchase Agreement with Nantahala (the "Note Purchase Agreement"), dated August 30, 2023.”
ZEVRA THERAPEUTICS, INC. entered into Credit Agreement with HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders valued at $100.0 million (effective 2024-04-05).
“On April 5, 2024 (the "Closing Date"), Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or the "Company"), as the borrower, entered into a credit agreement (the "Credit Agreement") among the Company, Acer Therapeutics, Inc., a Delaware corporation ("Acer"), Epyon Therapeutics, Inc., a Delaware corporation ("Epyon"), and Zevra Denmark A/S, a public limited liability company organized under the laws of Denmark (together with Acer and Epyon, collectively, the "Guarantors"), HCR Stafford Fund II, L.P., HCR Potomac Fund II, L.P., and Perceptive Credit Holdings IV, LP as lenders (collectively, the "Lenders"), and Alter Domus (US) LLC, as administrative agent (the "Administrative Agent").”
ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2023 results: revenue $13.2M.
“Corporate Updates Launch of OLPRUVA ® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M Conference call scheduled for today, March 28, 2024, at 4:30 p.m. ET Celebration, FL – March 28, 2024 – Zevra Therapeutics, Inc. (NasdaqGS:”
ZEVRA THERAPEUTICS, INC. reported that prior financial statements should not be relied upon.
“and for the fiscal years ended December 31, 2022 and December 31, 2021, included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, (collectively, the “Prior Financial Statements”) should no longer be relied upon. In connection with the preparation of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Form 10-K”), the Audit Committee concluded that, in prior years it had not appropriately accounted for certain common stock warrants as liabilities. These errors led to understatements of derivative and warrant liability and additional paid-in capital and fluctuations in fair value adjustment related to derivative and warrant liability during the impacted periods. We estimate that the impacts to the periods reported in the Prior Financial Statements will result in an increase to previously reported fair valu”
ZEVRA THERAPEUTICS, INC.: Amended and restated bylaws effective February 22, 2024 to address universal proxy rules, update stockholder nomination and proposal disclosure, and require proxy card color distinction (effective 2024-02-22).
“On February 22, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) approved and adopted the Company’s amended and restated bylaws (the “Amended and Restated Bylaws”) which became effective the same day.”
Alvin Shih, M.D. was appointed as director at ZEVRA THERAPEUTICS, INC..
“On January 20, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Alvin Shih, M.D. to serve as a director of the Company, effective immediately.”
ZEVRA THERAPEUTICS, INC. completed an acquisition involving Acer Therapeutics Inc. for 0.1210 validly issued, fully paid and non-assessable shares of Zevra common stock, $0.0001 par value per share, and one CVR (closed 2023-11-17).
“Completion of Acquisition or Disposition of Assets On November 17, 2023 (the “ Closing Date ”), Zevra completed the previously announced acquisition of Acer Therapeutics Inc., a Delaware corporation (“ Acer ”), pursuant to the Agreement and Plan of Merger (the “ Merger Agreement ”), dated August 30, 2023, by and among Zevra, Aspen Z Merger Sub, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Zevra (“ Merger Sub ”), and Acer.”
ZEVRA THERAPEUTICS, INC. reported the quarter ended September 30, 2023 results: revenue Net revenue of $2.9M for Q3 2023.
“er 2023 Financial Results Arimoclomol NDA resubmission remains on track for end of year filing Proposed acquisition of Acer Therapeutics on track to close Q4 2023 and will diversify Zevra ’ s revenue with FDA-approved OLPRUVA ® for urea cycle disorders (UCDs) Net revenue of $2.9M for Q3 2023 Ended Q3 2023 with $83.4M in cash, cash equivalents, and investments, supporting our forecasted cash runway into 2026 Conference call and live audio webcast scheduled for today, Nov 7, 2023, 8:00 a.m.”
Joseph B. Saluri resigned as Board member at ZEVRA THERAPEUTICS, INC..
“Resignation of Joseph B. Saluri from B”
Christal M.M. Mickle changed role as Chief Development Officer at ZEVRA THERAPEUTICS, INC..
“succeeding Christal M.M. Mickle., the Company’s former interim President and Chief Executive Officer, in such role. Ms. Mickle will continue serving in her role as Chief Development Officer.”
Neil F. McFarlane was appointed as member of the Board at ZEVRA THERAPEUTICS, INC..
“Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.”
Neil F. McFarlane was appointed as President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
“appointed Neil F. McFarlane to serve as the Company’s President and Chief Executive Officer, effective October 10, 2023”
ZEVRA THERAPEUTICS, INC. entered into Agreement and Plan of Merger with Acer Therapeutics Inc. (effective 2023-08-30).
“On August 30, 2023, Zevra Therapeutics, Inc., a Delaware corporation (“ Zevra ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Zevra, Aspen Z Merger Sub, Inc., a Delaware corporation and an indirect wholly-owned subsidiary of Zevra (“ Merger Sub ”), and Acer Therapeutics Inc., a Delaware corporation (“ Acer ”).”
ZEVRA THERAPEUTICS, INC. reported second quarter ended June 30, 2023 results: revenue $8.5 million, net income ($5.1) million, EPS ($0.15).
“Net revenue for Q2 2023 was $8.5 million compared to Q2 2022 net revenue of $1.3 million.”
Matthew R. Plooster resigned as member of the Board at ZEVRA THERAPEUTICS, INC..
“On August 7, 2023, Matthew R. Plooster, a member of the Board of the Company, resigned from such position, effectively immediately after the appointment of Mr. Anderson.”
Thomas Anderson was appointed as Class III director at ZEVRA THERAPEUTICS, INC..
“On August 7, 2023, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Thomas Anderson to serve as a director of the Company, effective immediately.”
ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.
“Net revenue for Q1 2023 was $2.9 million compared to Q1 2022 net revenue of $4.0 million.”
Christal M. M. Mickle was appointed as interim President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
“On May 13, 2023, Zevra’s Board of Directors (the “Board”) appointed Christal M.M. Mickle, Zevra’s Chief Development Officer, as Zevra’s interim President and Chief Executive Officer”
Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
“As previously reported, Richard W. Pascoe resigned as Zevra’s Chief Executive Officer, effective as of the Effective Date.”
Joseph B. Saluri departed as Director at ZEVRA THERAPEUTICS, INC..
“on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.”
Matthew R. Plooster departed as Director at ZEVRA THERAPEUTICS, INC..
“on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.”
Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
“On May 5, 2023, Richard W. Pascoe, the Chief Executive Officer of Zevra Therapeutics, Inc. (the “Company” or “Zevra”), resigned as the Company’s Chief Executive Officer, effective as of June 1, 2023.”
ZEVRA THERAPEUTICS, INC. shareholders approved The Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Compan at the 2023-04-25 meeting.
“Finally, the Mangless Proposal to adopt a resolution that would repeal any provision of the Company’s Amended and Restated Bylaws in effect at the time of the Annual Meeting that was not included in the Company’s Amended and Restated Bylaws in effect as of January 1, 2023 (other than the change of the Company’s name) was approved”
ZEVRA THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023 at the 2023-04-25 meeting.
“the stockholders of the Company ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023”
ZEVRA THERAPEUTICS, INC. shareholders approved Election of three Class II directors to the Company’s board of directors to hold office until the 2026 annual meeting of stockholders at the 2023-04-25 meeting.
“each of John B. Bode, Douglas W. Calder, and Corey Watton was elected as a director of the Company”
Travis Mickle resigned as Director at ZEVRA THERAPEUTICS, INC..
“to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.”
Wendy L. Dixon was appointed as Director at ZEVRA THERAPEUTICS, INC..
“the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Wendy L. Dixon, Ph.D. to serve as a director of the Company, effective immediately following the conclusion of the Company’s 2023 Annual Meeting of Stockholders (the "2023 Annual Meeting") to be held on April 25, 2023, to fill the vacancy resulting from Dr. Travis Mickle's resignation from the Board effective as of that day.”
ZEVRA THERAPEUTICS, INC. reported fourth quarter and fiscal year ended December 31, 2022 results: revenue $2.3 million, net income ($9.0) million, or ($0.26) per basic and diluted share, EPS ($0.26) per basic and diluted share.
“Page 3 Overview of Fourth Quarter (Q4) and Full-Year (FY) 2022 Financial Results: Net revenue for Q4 2022 was $2.3 million, as compared to Q4 2021 net revenue of $2.6 million. Q4 2022 net revenue was primarily driven by ongoing reimbursements received from the French early access program for arimoclomol, AZSTARYS® royalty revenues and consulting fees.”
ZEVRA THERAPEUTICS, INC.: Amended and restated bylaws to reflect name change to Zevra Therapeutics, Inc (effective 2023-02-21).
“The Company also amended and restated its amended and restated bylaws (the “Amended and Restated Bylaws”) effective on February 21, 2023, to reflect the Name Change.”
ZEVRA THERAPEUTICS, INC.: Changed corporate name to Zevra Therapeutics, Inc. via certificate of amendment to certificate of incorporation (effective 2023-02-21).
“Effective February 21, 2023, KemPharm, Inc. (the “Company”) changed its corporate name to Zevra Therapeutics, Inc. (the “Name Change”) pursuant to a certificate of amendment to the Company’s certificate of incorporation (the “Charter Amendment”)”
Matthew R. Plooster was appointed as Chairman of the Board at ZEVRA THERAPEUTICS, INC..
“Additionally, the Board has appointed Matthew R. Plooster, a member of the Board, as the Chairman of the Board.”
Travis C. Mickle resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
“On January 6, 2023, Dr. Mickle resigned his role (i) as Chief Executive Officer, effective immediately, and (ii) as President and as a member of the Board, in each case, effective as of the date of the Company’s 2023 Annual Meeting of Stockholders.”
Richard W. Pascoe was appointed as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..
“On January 6, 2023, the Board of Directors (the “Board”) of KemPharm, Inc. (the “Company”) appointed Richard W. Pascoe to serve as the Company’s Chief Executive Officer, effective immediately.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.